SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences:
Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference
Date: Monday, November 6, 2023
Time: 2:30 p.m. ET
Stifel 2023 Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 10:20 a.m. ET
Jefferies London Healthcare Conference
Date: Wednesday, November 15, 2023
Time: 11:30 a.m. ET
Evercore ISI 6th Annual HealthCONx Conference
Date: Tuesday, November 28, 2023
Time: 11:15 a.m. ET
A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.
Investor Contacts:
Noel Kurdi
VP of Investor Relations
Apogee Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Bill Slattery
THRUST Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Dan Budwick 1AB Media
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$47.71 |
| Daily Change: | 0.69 1.47 |
| Daily Volume: | 650,586 |
| Market Cap: | US$2.070B |
December 02, 2024 November 12, 2024 October 16, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
